Table 4.
KEGG pathway associating with predicted targets of miRNAs exhibiting >2-fold changes in response to both concentrations of EGCG
| Pathway | Count | P | Q |
|---|---|---|---|
| MAPK signaling pathway | 52 | 2.25E-29 | 3.93E-27 |
| Focal adhesion | 37 | 1.44E-20 | 2.47E-19 |
| Regulation of actin cytoskeleton | 38 | 1.55E-20 | 2.47E-19 |
| Insulin signaling pathway | 29 | 2.62E-18 | 3.53E-17 |
| Axon guidance | 26 | 5.25E-16 | 3.83E-15 |
| CAMs | 26 | 1.14E-15 | 7.67E-15 |
| Wnt signaling pathway | 27 | 3.25E-15 | 1.84E-14 |
| Colorectal cancer | 20 | 3.61E-14 | 1.66E-13 |
| ErbB signaling pathway | 19 | 8.38E-13 | 2.99E-12 |
| Adherens junction | 18 | 1.54E-12 | 5.38E-12 |
| Prostate cancer | 18 | 1.08E-11 | 2.97E-11 |
| Gap junction | 18 | 2.89E-11 | 7.12E-11 |
| Melanoma | 16 | 3.19E-11 | 7.75E-11 |
| Glioma | 15 | 9.14E-11 | 1.97E-10 |
| Neuroactive ligand-receptor interaction | 28 | 1.93E-10 | 3.93E-10 |
| Epithelial cell signaling in Helicobacter pylori infection | 15 | 2.82E-10 | 5.54E-10 |
| Pancreatic cancer | 15 | 5.28E-10 | 1.02E-09 |
| Endometrial cancer | 13 | 5.60E-10 | 1.06E-09 |
| Nonsmall cell lung cancer | 13 | 9.31E-10 | 1.73E-09 |
| Phosphatidylinositol signaling system | 15 | 9.59E-10 | 1.77E-09 |
| Leukocyte transendothelial migration | 18 | 2.56E-09 | 4.39E-09 |
| Calcium signaling pathway | 22 | 3.16E-09 | 5.32E-09 |
| Melanogenesis | 16 | 1.19E-08 | 1.81E-08 |
| Fc epsilon RI signaling pathway | 14 | 1.50E-08 | 2.26E-08 |
| Type II diabetes mellitus | 11 | 1.54E-08 | 2.31E-08 |
| Glycerophospholipid metabolism | 13 | 2.27E-08 | 3.33E-08 |
| B-cell receptor signaling pathway | 13 | 6.43E-08 | 9.15E-08 |
| GnRH signaling pathway | 15 | 1.20E-07 | 1.65E-07 |
| Adipocytokine signaling pathway | 12 | 1.41E-07 | 1.89E-07 |
| T-cell receptor signaling pathway | 15 | 1.55E-07 | 2.02E-07 |
EGCG: Epigallocatechin-3-gallate; miRNAs: microRNAs; MAPK: Mitogen-activated protein kinase; CAMs: Cell adhesion molecules; KEGG: Kyoto Encyclopedia of Genes and Genomes.